{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T14:52:27Z","timestamp":1779893547214,"version":"3.53.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Oncolytic viruses are cancer therapies that selectively replicate in tumors, deliver therapeutic genes, and stimulate immune responses. Combining these viruses with immune-boosting agents could enhance their effectiveness. Thymopentin (TP5), an immune-modulating peptide, may enhance the antitumour efficacy of ADV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We tested TP5 combined with adenovirus type 5 in tumor models, measuring tumor growth and immune changes using flow cytometry and antibody-based cell depletion. A modified oncolytic adenovirus producing TP5 (ADV-TP5) was created using gene editing and tested in mice and human immune cell-engrafted tumor models. TP5 was also combined with herpes simplex virus and vaccinia virus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Here we show that combining adenovirus (ADV) with thymopentin (TP5) reprograms the tumor microenvironment and enhances antitumor efficacy in xenograft models. ADV\u2009+\u2009TP5 increases proinflammatory macrophages and cytotoxic CD8\n                      <jats:sup>+<\/jats:sup>\n                      T-cell infiltration while stimulating long-term immune memory. We further engineer an oncolytic adenovirus expressing TP5 (ADV-TP5), which demonstrates superior tumor suppression compared to unmodified ADV in mice and human immune cell-engrafted models. TP5 also amplifies responses when combined with other oncolytic viruses (e.g., herpes simplex virus, vaccinia virus), supporting its role as a broad-spectrum adjuvant for clinical virotherapies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      TP5 strengthens oncolytic virotherapy by orchestrating macrophages and CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells to attack tumors. Its dual use, as a combination drug or engineered into viruses, offers a practical strategy to improve clinical outcomes. This approach provides a low-cost method to amplify oncolytic virus efficacy and inspires designs where single therapies mimic combination effects, advancing accessible cancer immunotherapy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s43856-026-01509-6","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T12:47:01Z","timestamp":1773665221000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Thymopentin enhances adenoviral oncolytic therapy by regulating macrophages and CD8+ T cells"],"prefix":"10.1038","volume":"6","author":[{"given":"Lingkai","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huawei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0521-0560","authenticated-orcid":false,"given":"Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiannan","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qilei","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangkun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junnan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2562-6275","authenticated-orcid":false,"given":"Xiaosong","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4753-2648","authenticated-orcid":false,"given":"Junhua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunping","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"1509_CR1","doi-asserted-by":"publisher","first-page":"e407","DOI":"10.1016\/S1470-2045(23)00385-6","volume":"24","author":"EM Garton","year":"2023","unstructured":"Garton, E. M. et al. Global oncology research and training at US National Cancer Institute-designated cancer centres: results of the 2021 Global Oncology Survey. Lancet Oncol. 24, e407\u2013e414 (2023).","journal-title":"Lancet Oncol."},{"key":"1509_CR2","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41571-021-00514-z","volume":"18","author":"I Soerjomataram","year":"2021","unstructured":"Soerjomataram, I. & Bray, F. Planning for tomorrow: global cancer incidence and the role of prevention 2020-2070. Nat. Rev. Clin. Oncol. 18, 663\u2013672 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1509_CR3","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1158\/1078-0432.CCR-17-1117","volume":"24","author":"EJ Mun","year":"2018","unstructured":"Mun, E. J., Babiker, H. M., Weinberg, U., Kirson, E. D. & Von Hoff, D. D. Tumor-treating fields: a fourth modality in cancer treatment. Clin. Cancer Res. 24, 266\u2013275 (2018).","journal-title":"Clin. Cancer Res."},{"key":"1509_CR4","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","volume":"575","author":"N Vasan","year":"2019","unstructured":"Vasan, N., Baselga, J. & Hyman, D. M. A view on drug resistance in cancer. Nature 575, 299\u2013309 (2019).","journal-title":"Nature"},{"key":"1509_CR5","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrd1984","volume":"5","author":"G Szak\u00e1cs","year":"2006","unstructured":"Szak\u00e1cs, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C. & Gottesman, M. M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5, 219\u2013234 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1509_CR6","doi-asserted-by":"publisher","unstructured":"Wang, P. et al. SENP3 inhibition suppresses hepatocellular carcinoma progression and improves the efficacy of anti-PD-1 immunotherapy. Cell Death Differ. https:\/\/doi.org\/10.1038\/s41418-024-01437-9 (2025).","DOI":"10.1038\/s41418-024-01437-9"},{"key":"1509_CR7","first-page":"86","volume":"70","author":"LB Kennedy","year":"2020","unstructured":"Kennedy, L. B. & Salama, A. K. S. A review of cancer immunotherapy toxicity. CA Cancer J. Clin. 70, 86\u2013104 (2020).","journal-title":"CA Cancer J. Clin."},{"key":"1509_CR8","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. & Zhang, Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol. Immunol. 17, 807\u2013821 (2020).","journal-title":"Cell Mol. Immunol."},{"key":"1509_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2022.100907","volume":"66","author":"K Pang","year":"2023","unstructured":"Pang, K. et al. Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1\/PD-L1 blockade. Drug Resist. Updates 66, 100907 (2023).","journal-title":"Drug Resist. Updates"},{"key":"1509_CR10","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abq3016","volume":"8","author":"JJ Peng","year":"2023","unstructured":"Peng, J. J., Wang, L., Li, Z., Ku, C. L. & Ho, P. C. Metabolic challenges and interventions in CAR T cell therapy. Sci. Immunol. 8, eabq3016 (2023).","journal-title":"Sci. Immunol."},{"key":"1509_CR11","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrd4663","volume":"14","author":"HL Kaufman","year":"2015","unstructured":"Kaufman, H. L., Kohlhapp, F. J. & Zloza, A. Oncolytic viruses: a new class of immunotherapy drugs. Nat. Rev. Drug Discov. 14, 642\u2013662 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1509_CR12","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.trecan.2022.10.003","volume":"9","author":"R Ma","year":"2023","unstructured":"Ma, R., Li, Z., Chiocca, E. A., Caligiuri, M. A. & Yu, J. The emerging field of oncolytic virus-based cancer immunotherapy. Trends Cancer 9, 122\u2013139 (2023).","journal-title":"Trends Cancer"},{"key":"1509_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ebiom.2018.04.020","volume":"31","author":"C Achard","year":"2018","unstructured":"Achard, C. et al. Lighting a fire in the tumor microenvironment using oncolytic immunotherapy. EBioMedicine 31, 17\u201324 (2018).","journal-title":"EBioMedicine"},{"key":"1509_CR14","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"1509_CR15","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1126\/science.1851332","volume":"252","author":"RL Martuza","year":"1991","unstructured":"Martuza, R. L., Malick, A., Markert, J. M., Ruffner, K. L. & Coen, D. M. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252, 854\u2013856 (1991).","journal-title":"Science"},{"key":"1509_CR16","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-020-00922-1","volume":"13","author":"O Hemminki","year":"2020","unstructured":"Hemminki, O., Dos Santos, J. M. & Hemminki, A. Oncolytic viruses for cancer immunotherapy. J. Hematol. Oncol. 13, 84 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"1509_CR17","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/gt.2011.176","volume":"19","author":"JD Dias","year":"2012","unstructured":"Dias, J. D. et al. Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. Gene Ther. 19, 988\u2013998 (2012).","journal-title":"Gene Ther."},{"key":"1509_CR18","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.1158\/0008-5472.CAN-09-3567","volume":"70","author":"V Cerullo","year":"2010","unstructured":"Cerullo, V. et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res. 70, 4297\u20134309 (2010).","journal-title":"Cancer Res."},{"key":"1509_CR19","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1158\/0008-5472.CAN-17-0468","volume":"77","author":"H Jiang","year":"2017","unstructured":"Jiang, H. et al. Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous cancer vaccination. Cancer Res. 77, 3894\u20133907 (2017).","journal-title":"Cancer Res."},{"key":"1509_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202103470","volume":"9","author":"L Ding","year":"2022","unstructured":"Ding, L. et al. An inter-supplementary biohybrid system based on natural killer cells for the combinational immunotherapy and virotherapy of cancer. Adv. Sci. 9, e2103470 (2022).","journal-title":"Adv. Sci."},{"key":"1509_CR21","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3233\/CBM-181286","volume":"23","author":"YH Xu","year":"2018","unstructured":"Xu, Y. H., Liu, S. H., Hao, F. R. & Zhang, Y. H. Recombinant adenovirus p53 combined with radiotherapy improves efficacy and safety in the treatment of head and neck lymphoma. Cancer Biomark. 23, 213\u2013220 (2018).","journal-title":"Cancer Biomark."},{"key":"1509_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101751","volume":"5","author":"K Liu","year":"2024","unstructured":"Liu, K. et al. Thymosin \u03b11 reverses oncolytic adenovirus-induced M2 polarization of macrophages to improve antitumor immunity and therapeutic efficacy. Cell Rep. Med. 5, 101751 (2024).","journal-title":"Cell Rep. Med."},{"key":"1509_CR23","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s13402-021-00633-w","volume":"44","author":"H Zhang","year":"2021","unstructured":"Zhang, H. et al. Recombinant adenovirus expressing the fusion protein PD1PVR improves CD8(+) T cell-mediated antitumor efficacy with long-term tumor-specific immune surveillance in hepatocellular carcinoma. Cell Oncol. 44, 1243\u20131255 (2021).","journal-title":"Cell Oncol."},{"key":"1509_CR24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.omto.2020.11.001","volume":"20","author":"H Zhang","year":"2021","unstructured":"Zhang, H. et al. Recombinant oncolytic adenovirus expressing a soluble PVR elicits long-term antitumor immune surveillance. Mol. Ther. Oncol. 20, 12\u201322 (2021).","journal-title":"Mol. Ther. Oncol."},{"key":"1509_CR25","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.canlet.2013.05.006","volume":"337","author":"J Li","year":"2013","unstructured":"Li, J. et al. The in vivo immunomodulatory and synergistic anti-tumor activity of thymosin \u03b11-thymopentin fusion peptide and its binding to TLR2. Cancer Lett. 337, 237\u2013247 (2013).","journal-title":"Cancer Lett."},{"key":"1509_CR26","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.bbamcr.2006.07.004","volume":"1763","author":"YZ Fan","year":"2006","unstructured":"Fan, Y. Z. et al. Thymopentin (TP5), an immunomodulatory peptide, suppresses proliferation and induces differentiation in HL-60 cells. Biochim Biophys. Acta 1763, 1059\u20131066 (2006).","journal-title":"Biochim Biophys. Acta"},{"key":"1509_CR27","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1021\/mp400722r","volume":"11","author":"C Wu","year":"2014","unstructured":"Wu, C. et al. Thymopentin nanoparticles engineered with high loading efficiency, improved pharmacokinetic properties, and enhanced immunostimulating effect using soybean phospholipid and PHBHHx polymer. Mol. Pharm. 11, 3371\u20133377 (2014).","journal-title":"Mol. Pharm."},{"key":"1509_CR28","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1126\/science.451537","volume":"204","author":"G Goldstein","year":"1979","unstructured":"Goldstein, G., Scheid, M. P., Boyse, E. A., Schlesinger, D. H. & Van Wauwe, J. A synthetic pentapeptide with biological activity characteristic of the thymic hormone thymopoietin. Science 204, 1309\u20131310 (1979).","journal-title":"Science"},{"key":"1509_CR29","first-page":"24","volume":"17","author":"C Xiaojing","year":"2017","unstructured":"Xiaojing, C., Yanfang, L., Yanqing, G. & Fangfang, C. Thymopentin improves cardiac function in older patients with chronic heart failure. Anatol. J. Cardiol. 17, 24\u201330 (2017).","journal-title":"Anatol. J. Cardiol."},{"key":"1509_CR30","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(83)92271-7","volume":"2","author":"F Mascart-Lemone","year":"1983","unstructured":"Mascart-Lemone, F. et al. Stimulation of cellular function by thymopentin (TP-5) in three AIDS patients. Lancet 2, 735\u2013736 (1983).","journal-title":"Lancet"},{"key":"1509_CR31","doi-asserted-by":"publisher","first-page":"e1348","DOI":"10.1371\/journal.pone.0001348","volume":"2","author":"Z Liu","year":"2007","unstructured":"Liu, Z., Zheng, X., Wang, J. & Wang, E. Molecular analysis of thymopentin binding to HLA-DR molecules. PLoS ONE 2, e1348 (2007).","journal-title":"PLoS ONE"},{"key":"1509_CR32","doi-asserted-by":"publisher","unstructured":"Ji, H. et al. Structural analysis of Salvia miltiorrhiza polysaccharide and its regulatory functions on T cells subsets in tumor-bearing mice combined with thymopentin. Int. J. Biol Macromol. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.133832 (2024).","DOI":"10.1016\/j.ijbiomac.2024.133832"},{"key":"1509_CR33","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1016\/j.ymthe.2019.07.019","volume":"27","author":"Y Zhang","year":"2019","unstructured":"Zhang, Y. et al. Recombinant adenovirus expressing a soluble fusion protein PD-1\/CD137L subverts the suppression of CD8(+) T cells in HCC. Mol. Ther. 27, 1906\u20131918 (2019).","journal-title":"Mol. Ther."},{"key":"1509_CR34","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1007\/s12272-001-2132-z","volume":"31","author":"D Gao","year":"2008","unstructured":"Gao, D., Zhang, X., Zhang, J., Cao, J. & Wang, F. Expression of thymosin alpha1-thymopentin fusion peptide in Pichia pastoris and its characterization. Arch. Pharm. Res. 31, 1471\u20131476 (2008).","journal-title":"Arch. Pharm. Res."},{"key":"1509_CR35","doi-asserted-by":"publisher","first-page":"11774","DOI":"10.1073\/pnas.1410626111","volume":"111","author":"K Kim","year":"2014","unstructured":"Kim, K. et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc. Natl. Acad. Sci. USA 111, 11774\u201311779 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1509_CR36","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1089\/hum.2009.135","volume":"20","author":"RJ Prestwich","year":"2009","unstructured":"Prestwich, R. J. et al. The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum. Gene Ther. 20, 1119\u20131132 (2009).","journal-title":"Hum. Gene Ther."},{"key":"1509_CR37","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.1245\/s10434-018-6803-0","volume":"25","author":"MC Perez","year":"2018","unstructured":"Perez, M. C. et al. Talimogene laherparepvec (TVEC) for the treatment of advanced melanoma: a single-institution experience. Ann. Surg. Oncol. 25, 3960\u20133965 (2018).","journal-title":"Ann. Surg. Oncol."},{"key":"1509_CR38","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1111\/cas.13027","volume":"107","author":"H Fukuhara","year":"2016","unstructured":"Fukuhara, H., Ino, Y. & Todo, T. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci. 107, 1373\u20131379 (2016).","journal-title":"Cancer Sci."},{"key":"1509_CR39","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/nm.3848","volume":"21","author":"CS Ilkow","year":"2015","unstructured":"Ilkow, C. S. et al. Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. Nat. Med. 21, 530\u2013536 (2015).","journal-title":"Nat. Med."},{"key":"1509_CR40","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41417-018-0042-1","volume":"26","author":"A Dyer","year":"2019","unstructured":"Dyer, A. et al. Turning cold tumours hot: oncolytic virotherapy gets up close and personal with other therapeutics at the 11th Oncolytic Virus Conference. Cancer Gene Ther. 26, 59\u201373 (2019).","journal-title":"Cancer Gene Ther."},{"key":"1509_CR41","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.annonc.2021.03.197","volume":"32","author":"AB Carpenter","year":"2021","unstructured":"Carpenter, A. B., Carpenter, A. M., Aiken, R. & Hanft, S. Oncolytic virus in gliomas: a review of human clinical investigations. Ann. Oncol. 32, 968\u2013982 (2021).","journal-title":"Ann. Oncol."},{"key":"1509_CR42","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.chom.2014.01.002","volume":"15","author":"J Bell","year":"2014","unstructured":"Bell, J. & McFadden, G. Viruses for tumor therapy. Cell Host Microbe 15, 260\u2013265 (2014).","journal-title":"Cell Host Microbe"},{"key":"1509_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2020.574007","volume":"8","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y., Wu, J., Zhang, H., Wei, J. & Wu, J. Extracellular vesicles-mimetic encapsulation improves oncolytic viro-immunotherapy in tumors with low coxsackie and adenovirus receptor. Front. Bioeng. Biotechnol. 8, 574007 (2020).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"1509_CR44","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1186\/s13046-019-1410-x","volume":"38","author":"M Xia","year":"2019","unstructured":"Xia, M. et al. Graphene oxide arms oncolytic measles virus for improved effectiveness of cancer therapy. J. Exp. Clin. Cancer Res. 38, 408 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1509_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2017.10.013","volume":"343","author":"J Schupp","year":"2019","unstructured":"Schupp, J. et al. Targeting myeloid cells in the tumor sustaining microenvironment. Cell Immunol. 343, 103713 (2019).","journal-title":"Cell Immunol."},{"key":"1509_CR46","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1172\/JCI80006","volume":"125","author":"S Ugel","year":"2015","unstructured":"Ugel, S., De Sanctis, F., Mandruzzato, S. & Bronte, V. Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J. Clin. Invest. 125, 3365\u20133376 (2015).","journal-title":"J. Clin. Invest."},{"key":"1509_CR47","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ccell.2017.07.006","volume":"32","author":"D Saha","year":"2017","unstructured":"Saha, D., Martuza, R. L. & Rabkin, S. D. Macrophage polarization contributes to glioblastoma eradication by combination immunovirotherapy and immune checkpoint blockade. Cancer Cell 32, 253\u2013267 e255 (2017).","journal-title":"Cancer Cell"},{"key":"1509_CR48","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/cac2.12579","volume":"44","author":"L Xiao","year":"2024","unstructured":"Xiao, L. et al. Find Me\u201d and \u201cEat Me\u201d signals: tools to drive phagocytic processes for modulating antitumor immunity. Cancer Commun. 44, 791\u2013832 (2024).","journal-title":"Cancer Commun."}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01509-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01509-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01509-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T12:02:15Z","timestamp":1777896135000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01509-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1509"],"URL":"https:\/\/doi.org\/10.1038\/s43856-026-01509-6","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"assertion":[{"value":"27 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.L., J.W., C.J., L.K., H.C., X.G. and Q.X. are named as inventors on the China patent application (no. 2024110168233), which is related to this work. Jinan Microecological Biomedicine Shandong Laboratory and Nanjing University are the applicants of this patent application. X.G. and Q.X. are employees of Jinan Microecological Biomedicine Shandong Laboratory. J.W. and C.J. are employees of Nanjing University. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"265"}}